Pharming Group (NASDAQ:PHAR) Shares Down 3.4% – Time to Sell?

Shares of Pharming Group (NASDAQ:PHAR) fell 3.4% on Monday . The company traded as low as $9.55 and last traded at $9.55. 455 shares traded hands during trading, a decline of 91% from the average session volume of 5,137 shares. The stock had previously closed at $9.89.

Analyst Ratings Changes

Several research firms recently weighed in on PHAR. Jefferies Financial Group started coverage on shares of Pharming Group in a report on Monday, December 9th. They set a “buy” rating and a $14.00 target price on the stock. Oppenheimer dropped their target price on Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. Finally, HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Tuesday, December 17th.

Pharming Group Price Performance

The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The business’s 50-day moving average price is $8.65 and its two-hundred day moving average price is $8.30. The firm has a market cap of $661.39 million, a price-to-earnings ratio of -37.50 and a beta of -0.08.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in shares of Pharming Group (NASDAQ:PHAR) by 75.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.